📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-09-11 17:24
0 analysed today
FollowTelegram
0
Today
151,859
All-time analysed
43,535
Positive
6,743
Negative
92,744
Neutral
8,769
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
5 announcements match the current filters (relevance ≥ 5).
Sunrest Lifescience Scraps Rights Issue Due to Insufficient Subscription
Sunrest Lifescience Limited has announced the dissolution of its proposed Rights Issue after failing to achieve the minimum subscription mandated under Regulation 86 of SEBI ICDR Regulations. The issue was originally open from August 18, 2026, to September 02, 2026, and extended until September 11, 2026. Following this board decision, the company will unblock all applicant funds. With a net worth of ₹19 Cr and debt of ₹9 Cr, the failure to raise capital limits the company's immediate equity financing options.
Confidence: HIGH
What changedThe planned Rights Issue has been officially cancelled, and blocked application funds are being released back to applicants.
Why it mattersThe inability to achieve minimum subscription indicates weak shareholder participation and deprives the company of planned equity capital to support business expansion or debt reduction.
Original Issue Closing Date: September 02, 2026Extended Closing Date: September 11, 2026Letter of Offer Date: August 07, 2026Company Total Debt (Context): ₹9 CrCompany Net Worth (Context): ₹19 Cr
📅 Short termNegative sentiment is likely to weigh on the stock following the failed capital raising and rejection of the rights offer by eligible shareholders.
📈 Long termManagement may need to rely on internal accruals or higher-cost debt to finance operations, potentially impacting leverage against its ₹19 Cr net worth.
⚠ Risk flags
- Capital shortfall risk due to failed rights issue
- Weak institutional or minority shareholder interest/participation
Key Highlights
Rights issue cancelled due to non-receipt of minimum subscription under SEBI ICDR Regulation 86
Board decided to unblock applicant funds immediately following the meeting on September 11, 2026
Subscription period initially ran from August 18, 2026, to September 02, 2026, before being extended to September 11, 2026
Issue was governed by terms set out in the Letter of Offer dated August 07, 2026
👀 What to Watch
Watch for company disclosures regarding alternative capital-raising plans or adjustments to capex and working capital management given the failed equity raise.
Subsidiary Hetvi Lifesciences Delivers ₹80.76 Lakh Towards ₹9.22 Cr GMSCL Order
Sunrest Lifescience announced an operational update regarding its 51.49%-owned subsidiary, Hetvi Lifesciences Private Limited. The subsidiary has an order valued at approximately ₹9.22 Crore from Gujarat Medical Services Corporation Limited. To date, work executed and delivered under this contract totals ₹80.76 Lakhs, with management noting that execution is progressing according to planned operational timelines.
Confidence: HIGH
What changedSunrest provided a milestone update on an active ₹9.22 Crore state institutional supply order.
Why it mattersDemonstrates ongoing operational execution at the subsidiary level, representing key revenue visibility against a consolidated net worth of ₹19 Crore.
Total Order Value: ₹9.22 Crore (Approx)Delivered Till Date: ₹80.76 LakhsOrder vs Net Worth: ~48.5%Subsidiary Stake: 51.49%
📅 Short termProvides operational clarity on institutional order fulfilment, indicating steady progress without major bottlenecks.
📈 Long termExecution capability with state procurement bodies like GMSCL aids credentials for securing larger institutional tenders in the future.
⚠ Risk flags
- Execution and payment turnaround delays typical of state government procurement contracts
- Subsidiary-level operational and audit dependencies
Key Highlights
Total order value from Gujarat Medical Services Corporation Limited is approx ₹9.22 Crore
Work executed and delivered till date stands at ₹80.76 Lakhs
Contract is executed through subsidiary Hetvi Lifesciences Private Limited (51.49% holding)
👀 What to Watch
Track the delivery run-rate of the remaining ~₹8.41 Crore contract value and its margin contribution in subsequent consolidated quarterly results.
1:1 Rights Issue at Rs 35: Sunrest Lifescience to double equity capital
Sunrest Lifescience has finalized a 1:1 rights issue, offering one new equity share for every existing share held as of the record date. The issue price is set at Rs 35 per share, representing a 12.5% discount to the current market price of Rs 40. The record date is fixed for August 10, 2026, leaving a very short window for investor action. This move will double the company's outstanding shares, resulting in significant immediate EPS dilution.
Confidence: HIGH
What changedThe company has moved from a proposal to a finalized execution plan for a 1:1 rights issue, including the price and record date.
Why it mattersThis is a major capital infusion relative to the company's current Rs 19 Cr net worth. While it provides funds for growth or debt reduction (current debt Rs 9 Cr), the 100% equity expansion will significantly dilute existing shareholders' earnings per share.
Rights Ratio: 1:1Issue Price: Rs 35Current Market Price: Rs 40.0Record Date: August 10, 2026Discount to CMP: 12.5%
📅 Short termThe stock price is likely to adjust downwards toward the ex-rights price following the record date. Expect volatility as investors trade Rights Entitlements.
📈 Long termThe long-term impact depends on the utilization of the raised capital; the company needs to deploy these funds into high-margin pharmaceutical products to offset the 100% dilution.
⚠ Risk flags
- 100% equity dilution
- Short notice period for record date
- History of internal control weaknesses (INR 100 lakh inventory adjustment)
Key Highlights
Rights entitlement ratio fixed at 1:1, effectively doubling the share count
Issue price set at Rs 35 per share, a discount of Rs 5 from the current price of Rs 40
Record date for eligibility established as August 10, 2026
International Securities Identification Number (ISIN) for Rights Entitlement is INE0PLZ20020
Board meeting for final approval concluded within 30 minutes on August 07, 2026
👀 What to Watch
Investors must monitor their demat accounts for the credit of Rights Entitlements (REs). To avoid value loss from dilution, shareholders should either subscribe to the issue or sell their REs on the exchange during the trading window.
1:1 Rights Issue: Sunrest Lifescience Sets August 10, 2026, as Record Date
Sunrest Lifescience has announced August 10, 2026, as the record date for its upcoming Rights Issue. The company is offering shares in a 1:1 ratio, meaning eligible shareholders will receive one new equity share for every one share held. This corporate action will double the company's total number of outstanding shares if fully subscribed. While the issue price was not disclosed in this specific filing, the face value is confirmed at ₹10 per share.
Confidence: HIGH
What changedThe company has finalized the timeline and eligibility criteria for a 1:1 rights issue, moving from a proposal to an active execution phase.
Why it mattersA 1:1 rights issue is a major capital event that will double the share count, impacting EPS and requiring significant capital deployment to maintain current ROCE levels (18.1%).
Rights Ratio: 1:1Record Date: 10-Aug-2026Face Value: ₹10Net Worth (Context): ₹19 CrEquity Dilution Potential: 100%
📅 Short termThe stock price may adjust downward on the ex-rights date to reflect the increased share count, often leading to short-term volatility.
📈 Long termThe long-term impact depends entirely on the issue price and whether the management can deploy the new capital to scale its pharmaceutical operations effectively.
⚠ Risk flags
- Significant equity dilution
- Issue price not yet disclosed
- Past inventory valuation errors (₹100 lakh adjustment) suggest internal control risks
Key Highlights
Rights entitlement ratio fixed at 1:1 (one new share for every one held)
Record date for eligibility established as August 10, 2026
Face value of the rights equity shares is ₹10 per share
Announcement follows a period where the company reported a March 2026 quarterly PAT of ₹6.57 cr
👀 What to Watch
Investors should monitor for the 'Letter of Offer' to identify the issue price and the specific purpose of the fundraise, as a 1:1 ratio will lead to significant equity dilution.
1:1 Rights Issue at Rs 35 per share; Record Date Aug 10, 2026
Sunrest Lifescience has announced a 1:1 rights issue to raise approximately Rs 15.02 crore by issuing 42.91 lakh shares. The issue price of Rs 35 represents a narrow 4.1% discount to the current market price of Rs 36.5. The record date is set for August 10, 2026, with the subscription period running from August 18 to September 2, 2026. This is a significant capital infusion, representing nearly 79% of the company's current net worth of Rs 19 crore.
Confidence: HIGH
What changedThe company has finalized the pricing, ratio, and timeline for its previously proposed rights issue, doubling its equity base.
Why it mattersThe fundraise is substantial (79% of net worth), providing significant capital for potential expansion or debt reduction, but it results in massive equity dilution for existing shareholders.
Issue Price: Rs 35Rights Ratio: 1:1Total Issue Size: Rs 15.02 crIssue vs Net Worth: ~79%Post-Issue Shares: 85,82,400
📅 Short termThe stock may experience volatility leading up to the record date of August 10. The narrow discount to the current market price offers limited incentive for participation if the market price drops.
📈 Long termThe structural impact depends on the deployment of the Rs 15.02 crore; if used for high-ROCE expansions, it could offset the 100% dilution over several quarters.
⚠ Risk flags
- 100% equity dilution
- Narrow discount to market price (4.1%)
- History of internal control weaknesses (Rs 100 lakh inventory valuation error)
Key Highlights
Rights ratio of 1:1 will double the total outstanding shares to 85,82,400
Issue price of Rs 35 per share includes a premium of Rs 25 over the Rs 10 face value
Total fundraise amount is approximately Rs 15.02 crore based on 42,91,200 shares
Record date for eligibility is August 10, 2026, with the issue closing on September 2, 2026
Issue price is at a narrow 4.1% discount to the current market price of Rs 36.5
👀 What to Watch
Investors should review the Letter of Offer to understand the specific use of proceeds and evaluate the impact of 100% equity dilution on future Earnings Per Share (EPS).
